ACHL:NSD-Achilles Therapeutics plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 5.85

Change

-0.10 (-1.68)%

Market Cap

USD 0.24B

Volume

0.02M

Avg Analyst Target

USD 11.00 (+88.03%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom. Address: 245 Hammersmith Road, London, United Kingdom, W6 8PW

Company Website : http://www.achillestx.com

Address : 245 Hammersmith Road, London, United Kingdom, W6 8PW

Employees : 153

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 18.95

Short Ratio : 2.20

52 Week Low : 5.45

Shorted Shares : 586,319

200 Day Moving Average : 10.29

Shorted Shares Previous Month : 591,841

50 Day Moving Average : 6.31

Short Percentage : 1.00%

Shares Held by Institutions : 50.95%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+6.68 (+1.54%)

 USD175.20B 51.28 41.56
BNTX BioNTech SE

-2.09 (-0.61%)

 USD82.22B 18.72 15.10
REGN Regeneron Pharmaceuticals Inc

+0.11 (+0.02%)

 USD69.19B 11.68 8.91
VRTX Vertex Pharmaceuticals Incorpo..

-1.53 (-0.82%)

 USD48.20B 24.50 16.63
BGNE BeiGene Ltd

-0.33 (-0.08%)

 USD41.72B N/A N/A
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
SGEN Seagen Inc

+4.15 (+2.51%)

 USD30.02B 51.49 39.11
GMAB Genmab A/S

-0.22 (-0.50%)

 USD28.07B 71.33 8.17
RPRX Royalty Pharma plc

-0.34 (-0.93%)

 USD22.24B 29.66 12.50
ALNY Alnylam Pharmaceuticals Inc

-1.94 (-1.05%)

 USD21.89B N/A N/A

ETFs Containing ACHL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.24B 42% F 36% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.73 98% A+ 95% A
Price / Cash Flow Ratio -9.36 55% F 72% C-
EV/EBITDA 0.93 52% F 91% A-
Management Effectiveness  
Return on Equity -25.07% 82% B- 38% F
Return on Invested Capital -23.20% 75% C 27% F
Return on Assets -14.13% 76% C 24% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.20 71% C- 62% D-
Short Percent 2.74% 72% C- 52% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.